The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 701–800 of 1,000
Maansson, C. T., Andersen, E. R., Ulhøi, M. P., Meldgaard, P., & Sørensen, B. S. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05259-3 · Cited by 3
Xue, W.-H., Li, X., Ding, Y.-Q., Wu, N., Pei, B., Ma, X.-Y., Xie, J., & Yang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1165040 · Cited by 3
Takeuchi, S., Hirata, K., Magota, K., Watanabe, S., Moku, R., Shiiya, A., Taguchi, J., Ariga, S., Goda, T., Ohhara, Y., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01019-9 · Cited by 3
Okano, N., Morizane, C., Okusaka, T., Sadachi, R., Kataoka, T., Kobayashi, S., Ikeda, M., Ozaka, M., Mizutani, T., Sugimori, K., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad220 · Cited by 3
Zhang, C., Zeng, J., Ye, C., Tian, K., & Xian, Z. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1383 · Cited by 3
NTRK3 -Rearranged Prostatic Acinar Adenocarcinoma: Report of a Patient and Review of the Literature
Whaley, R. D., Tekin, B., McCarthy, M. R., Zia, H. M., Pitel, B. A., Al‐Kateb, H., Cheville, J. C., & Gupta, S. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969241253197 · Cited by 3
Vince, C. S. C., Brassesco, M. S., Mançano, B. M., Gregianin, L. J., Carbone, E. K., Castro, A. D. A. E., Yamachira, V. S., da Silva, R. Z. M., Mariano, C. S., da Mata, J. F., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00713 · Cited by 3
Yamazaki, H., Sugimori, M., & Saito, A. (2024) · Surgical Case Reports · doi:10.1186/s40792-024-01971-1 · Cited by 3
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
Secretory Carcinoma of the Thyroid: A Case Report and Update of Literature
Chu, Y., Kobrossy, B., Schwartz, D., Bruns, A. D., & Marsh, J. (2024) · Head and Neck Pathology · doi:10.1007/s12105-024-01693-8 · Cited by 3
Klinische und molekulare Epidemiologie maligner Speicheldrüsentumore
Jansen, L., Nachtsheim, L., Mayer, M., Arolt, C., Quaas, A., Klußmann, J. P., & Wolber, P. (2024) · Laryngo-Rhino-Otologie · doi:10.1055/a-2373-5741 · Cited by 3
Precision Oncology in Melanoma: Changing Practices
Dougherty, S. C., Flowers, W. L., & Gaughan, E. M. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267781 · Cited by 3
GIST avancées : quels traitements en 2022 ?
Mas, L., & Bachet, J. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.06.009 · Cited by 3
Perez, J. M. M. T., García‐Cosío, M., García‐Castaño, A., Gomà, M., Mesía, R., Ruiz‐Bravo, E., Soria-Rivas, A., Castillo, P., Braña, I., & Alberola‐Ferranti, M. (2022) · Revista Española de Patología · doi:10.1016/j.patol.2022.06.003 · Cited by 3
Paving the path towards tissue-agnostic drug approval in oncology
Tourneau, C. L., Bièche, I., & Kamal, M. T. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.07.731 · Cited by 3
Reimbursement Team (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.199 · Cited by 2
SarkoLife: quality of life in patients undergoing multimodal soft tissue sarcoma treatment
Hoffmann, S., Hoffmann, T., Potkrajcic, V., Deinzer, C. K. W., Benzler, K., Zender, L., Daigeler, A., & Thiel, J. T. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03632-x · Cited by 2
Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances
Okano, N., Pirozzi, A., Abidoye, O., Hoyek, C., Eslinger, C. R., Zheng-Lin, B., Jamal, F., Sahwan, O., Sonbol, M. B., Usón, P. L. S., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf052 · Cited by 2
Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview
Citterio, C., Vecchia, S., Mordenti, P., Anselmi, E., Ratti, M., Guasconi, M., & Orlandi, E. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030026 · Cited by 2
Huo, H., Li, H., Yang, X., Wang, S., Zhao, Y., & Yang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1581920 · Cited by 2
Shibata, Y., Oba, A., Shimane, G., Miyata, T., Tauchi, J., Baba, H., Maekawa, A., Kobayashi, K., Ono, Y., Sasaki, T., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110369 · Cited by 2
Zhang, Y. H., Ding, T., Cheng, R.-F., Wang, Y., & Wu, J. (2025) · Clinical Endocrinology · doi:10.1111/cen.70013 · Cited by 2
Zhang, X., Yuan, B., Li, C., Wang, H., Wei, S., Tian, J., & Duan, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70153 · Cited by 2
Tsumura, H., Koguchi, D., Tabata, K.-I., Shimura, S., Hirano, S., Satoh, T., Takahashi, K., Araki, N., Kawata, R., Watanabe, A., et al. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2903 · Cited by 2
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025)
García-Sáenz, J. Á., Blancas, I., Echavarría, I., Hinojo, C., Vila, M. M., Antón, F. M., Pernas, S., y Cajal, T. R., Ribelles, N., & Bellet, M. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04102-w · Cited by 2
KRAS-Wild Pancreatic Cancer—More Targets than Treatment Possibilities?
Krupa, K., Fudalej, M. M., Miski, H., Włoszek, E., Szymczak, M., Badowska-Kozakiewicz, A. M., Czerw, A. I., & Deptała, A. (2025) · Cancers · doi:10.3390/cancers17233769 · Cited by 2
Schraa, S. J., Laclé, M. M., Zwart, K., Gort, E. H., de Leng, W. W. J., Koopman, M., Vink, G. R., & Bol, G. M. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100180 · Cited by 2
Joung, R. H., & Snyder, R. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-515560 · Cited by 2
Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)
Hernando, J., López, C., García‐Álvarez, A., Losada, S. A., Martínez‐Sáez, O., Pérez, C. G., Almaraz, R. L., Morillas, R. S., Liceaga, J. R., Freire, L. F., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116252 · Cited by 2
Harvey, A. M., Walser, E., Lahamm-Andraos, R., Yeo, C. T., Wolfe, S. A., Stretch, C., Craig, S. J., & Bathe, O. F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1737469 · Cited by 2
Targeted therapies in pediatric oncology: A start
Shah, N. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201146 · Cited by 2
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2
Recent Advances in Targeted Therapies for Adult Gliomas
Lasica, A. B., Tang, A. R., Iqbal, A., Nakhate, V., & Wen, P. Y. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01484-4 · Cited by 2
Jiang, T., Zhou, P., Shen, Y., Lin, J., Li, Y., Shen, X., Fang, L., Xu, P., Xu, Z., Wang, L., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00444-1 · Cited by 2
The role of the molecular tumor board: learnings from the ROME trial
Marchetti, P., Curigliano, G., Westphalen, C. B., Biffoni, M., Lonardi, S., Scagnoli, S., Fornaro, L., Guarneri, V., Giorgi, U. D., Ascierto, P. A., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01386-1 · Cited by 2
Zhang, H., Dreuzy, E. D., Huang, Y. Z., Shin, S., Huang, Q., Delaidelli, A., Yang, X., Adamiak, V., Lytle, A. G., Arzoo, A., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1036 · Cited by 2
Zhu, Y., Ma, K., Hao, Q., Fu, K., Hei, F., Ning, S., Yin, Z., Guo, W., Zou, H., & Tan, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02667-w · Cited by 2
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types
Yang, S., Repetto, M., Rudzinski, E. R., Li, M. M., Roy, A., Gutstein, L., Huang, K., Wu, J., Bender, J. G., Brega, N. M., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01150 · Cited by 2
Self-citationUnderstanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?
Myat, Y. M., Thein, K. Z., Han, M. M., Ahluwalia, M. S., Mukherjee, S., & Aung, K. L. (2026) · Cancers · doi:10.3390/cancers18101568 · Cited by 2
Nesper‐Brock, M., Metzler, M., Wotschofsky, Z., Reinhardt, D., Fischer, M. J., Rutkowski, S., Kratz, C. P., Thorwarth, A., Einsiedel, H. G., Schrappe, M., et al. (2021) · Der Onkologe · doi:10.1007/s00761-021-00928-5 · Cited by 2
Self-citationChallenges of Treating Young Women With Cancer in the Era of New Oncologic Treatments
Bourlon, M. T., Barragán-Carrillo, R., Mesa-Chávez, F., & Villarreal-Garza, C. M. (2021) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.21000312 · Cited by 2
Therapiekonzepte des fortgeschrittenen Lungenkarzinoms im Stadium IV
Schulz, C. K. J. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1393-7697 · Cited by 2
SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021)
de la Haba-Rodríguez, J., Lloret, F. F., Salgado, M. Á. V., Oré-Arce, M., Cardeña-Gutiérrez, A., Jiménez, J. G.-D., Zambrano, C. B., Rodríguez-Alonso, R. M., López‐López, R., & Salas, N. R. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02817-8 · Cited by 2
Gourmel, A., Rouette, A., Benlimame, N., El-Jalbout, R., Dubé, M., Théorêt, Y., Piché, N., Labonte, S., Sinnett, D., Cellot, S., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00200 · Cited by 2
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Genomic landscape of anaplastic thyroid cancer and implications on therapy
Cheng, L., & Newbold, K. L. (2023) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2023.100458 · Cited by 2
RETaliation—Tackling Rare Resistance Alterations to Osimertinib
Krebs, M., & Popat, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0993 · Cited by 2
The history of targeted therapy
Gerk, I. (2023) · Practical oncology · doi:10.31917/2402119 · Cited by 2
The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma
Wang, H., Qi, L., Zhong, C., Fang, X., & Yuan, Y. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231180840 · Cited by 2
遺伝子から頭頸部がんを診る―唾液腺癌における遺伝子異常 up to date―
加納, 里. (2023) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.126.9_1041 · Cited by 2
Treatment of glioblastoma in Greenlandic patients
Frandsen, S., Pedersen, A. J., Gredal, O., Møller, S., Geisler, U. W., & Nørøxe, D. S. (2023) · International Journal of Circumpolar Health · doi:10.1080/22423982.2023.2285077 · Cited by 2
Suzuki, N., Idogawa, M., Emori, M., Murase, K., Arihara, Y., Nakamura, H., Usami, M., Kubo, T., Kinoshita, I., Sugita, S., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.2879-23 · Cited by 2
Yun, K. M., Narezkina, A., Redfern, C. H., Velasco, K., & Bazhenova, L. A. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00265 · Cited by 2
Chen, Y., Ma, J., Gao, Q., Gai, Y., Sun, Y., & Wang, M. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100329 · Cited by 2
Rosell, R., Pedraz‐Valdunciel, C., Jain, A. S., Shivamallu, C., & Aguilar, A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2320710 · Cited by 2
Role of molecular biology in the management of pancreatic cancer
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Tarabay, A., Valéry, M., Fuerea, A. C., Pudlarz, T., Conroy, T., Hollebecque, A., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i7.2902 · Cited by 2
Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer
Kou, F.-R., Li, J., Wang, Z., Xu, T., Qian, J.-J., Zhang, E.-L., Zhang, L., Shen, L., & Wang, X. (2023) · Gastroenterology report · doi:10.1093/gastro/goae092 · Cited by 2
Larotrectinib in NTRK3 fusion–positive metastatic secretory carcinoma of the breast: A case study
Dietrich, M. F., & Velez, M. (2024) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2024.100334 · Cited by 2
Querzoli, G., Levit, A. S., Varga, Z., & Foschini, M. P. (2025) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2024.12.003 · Cited by 2
Three locally invasive infantile fibrosarcoma cases treated with larotrectinib
Tanyıldız, H. G., Yılmaz, Y., Dalay, D., Şahin, Ş., Karaman, S., Ünüvar, A., Karakaş, Z., & Tuğcu, D. (2025) · The Turkish Journal of Pediatrics · doi:10.24953/turkjpediatr.2025.4557 · Cited by 2
Clinical characterization and therapeutic targeting of fusion genes in oncology
Morand, S. M., Rager, L. E., Craig, D. J., Nemunaitis, A., Choucair, K., Rao, D., Stanbery, L., Phinney, R. C., Walter, A., Ghisoli, M. L., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2477974 · Cited by 2
Xiang, W., Yuan, W., Ren, L., Huang, W. L., Liang, H., Huang, J., Luan, L., Chen, X., & Hou, Y. (2025) · Diagnostic Pathology · doi:10.1186/s13000-025-01630-5 · Cited by 2
Comparative analysis of RNA expression identifies effective targeted drug in myoepithelial carcinoma
Vasquez, Y. A., Sanders, L., Beale, H. C., Lyle, A. G., Kephart, E. T., Learned, K., Peralez, J., Li, A., Huang, M., Pyke‐Grimm, K. A., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00918-5 · Cited by 2
Wang, Q., Lv, N., Xu, D., Wu, Y. F., Wu, J., Gao, W., Wei, J., Xiao, B., Tu, M., & Jiang, K. (2025) · BMC Cancer · doi:10.1186/s12885-025-14601-2 · Cited by 2
Terashima, Y., Park, S., Ikeuchi, H., Hayashi, T., Kojima, S., Ueno, T., Ikegami, M., Kitada, R., Suehara, Y., Tanaka, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70142 · Cited by 2
Nouveautés sur la caractérisation moléculaire des sarcomes des tissus mous
Watson, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.03.010 · Cited by 2
Molecular Alterations in Pediatric Solid Tumors
Slack, J. C., & Church, A. J. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.010 · Cited by 2
By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with It
Sümbül, A. T., Sedef, A. M., Karaçin, C., Bilir, C., & Akagündüz, B. (2022) · Journal of Oncological Sciences · doi:10.37047/jos.2022-90068 · Cited by 2
NTRK3 mutation in secretory carcinoma of the parotid gland: A Case report
Alkaabba, F., Alloghbi, A., Deajim, Y. A., Sukkari, M. W., Khan, M. Y. A., & Sukari, A. W. (2022) · Clinical Case Reports · doi:10.1002/ccr3.6243 · Cited by 2
Cholangiocarcinomes avancés et gènes de fusion
Mas, L., Perrier, A., Coulet, F., & Bachet, J. (2022) · Bulletin du Cancer · doi:10.1016/s0007-4551(22)00466-0 · Cited by 2
Targeted Therapies in Non-small Cell Lung Cancer
Bauman, J. R., & Edelman, M. J. (2022) · Medical radiology · doi:10.1007/174_2022_312 · Cited by 2
Neue Therapieansätze für Speicheldrüsenmalignome
Nachtsheim, L., Prinz, J., Arolt, C., Quaas, A., Meyer, M. F., Klußmann, J. P., & Wolber, P. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-2061-5759 · Cited by 2
Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer
Poh, A. R., Sammour, A., Mathai, J., Peverall, J., Vliet, C. V., Asadi, K., & Parakh, S. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-113 · Cited by 2
Patel, A., LaBarge, B., King, T. S., Pradhan, S., Warrick, J., & Goyal, N. (2023) · SAGE Open Medicine · doi:10.1177/20503121231200103 · Cited by 2
Unifying Themes in Urothelial Cancers
Chester, J. D. (2020) · European Urology · doi:10.1016/j.eururo.2020.09.045 · Cited by 2
A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma
Mascarenhas, L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01296 · Cited by 2
Self-citationEditorial: Clinical therapy of brain tumors
Huang, B., Zhao, H., Yang, J., Liu, F., Caruso, G., Zhang, H., & Chen, L. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1610463 · Cited by 2
High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
Groothuis, P. G., Penel, N., Italiano, A., Kotecki, N., Dijcks, F. A., & Dokter, W. H. A. (2021) · Cancers · doi:10.3390/cancers13194841 · Cited by 1
Ozcan, G., Gautam, G., Cunha, T. D., Becker, E. C., & Perosevic, N. (2022) · Cureus · doi:10.7759/cureus.26421 · Cited by 1
Offenbacher, R., Kobets, A. J., Dalvi, N., Hsu, K. A., Chin, S. S., Snuderl, M., Levy, A., & Martin, A. M. (2022) · Child s Nervous System · doi:10.1007/s00381-022-05662-w · Cited by 1
Targeted mutation-based therapy for intrahepatic cholangiocarcinoma
Yang, F., Qiu, Y., & Yi, B. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2023.68 · Cited by 1
Hu, L., Sun, Q., Tang, L., Cai, M., Qian, W., Dou, T., Wang, H., Wu, Y., & Liu, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01334-y · Cited by 1
Grünwald, F., Sabet, A., Ngoc, C. N., Kranert, W. T., & Groener, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_11 · Cited by 1
Glioblastom – aktuelle Therapiekonzepte
Rieger, D., Renovanz, M., Kurz, S. C., Bombach, P., Paulsen, F., Roder, C., Tatagiba, M. S., Niyazi, M., & Tabatabai, G. (2024) · Die Onkologie · doi:10.1007/s00761-024-01473-7 · Cited by 1
Iwata, S. (2024) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000002998 · Cited by 1
Integrative analysis of PTEN ‐related hub genes and validating drug targets for colorectal cancer
Wang, G., Zhu, Z. M., & Wang, K. (2024) · Precision Medical Sciences · doi:10.1002/prm2.12126 · Cited by 1
Targeted Molecular Profiling of Non-small Cell Lung Cancer in India
Dhungel, A., Mudagal, M. P., Sharma, U., Sariwan, S., Sharma, D., Vada, S., Janadri, S., Haribabu, T. E., & Matada, G. S. P. (2024) · Journal of Advanced Immunopharmacology · doi:10.5812/jai-141895 · Cited by 1
Patel, H. B., Dave, R. H., Vadariya, S., Hirpara, H., & Patel, T. (2024) · Biotechnology Journal International · doi:10.9734/bji/2024/v28i4724 · Cited by 1
Hepatotoxicity of Anti-cancer Drugs
Bayram, D., & Uçar, G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_344 · Cited by 1
Goto, Y., Watanabe, S., Yanagimura, N., Arita, M., Sato, M., Nozaki, K., Tanaka, T., Saida, Y., Maemondo, M., Kobayashi, K., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108505 · Cited by 1
Intracranial Activity of Sotorasib in KRAS G12C -Mutated Recurrent Glioblastoma
Morgan, K. P., Carroll, A., Rauf, Y., Khagi, S., & Cipriani, A. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00833 · Cited by 1
Strategies for the Treatment of Desmoplastic Small Round Cell Tumor: A Case Series
Offenbacher, R., Lazar, P., Fabish, L., Fox, J. L., Lee, A., Loeb, D. M., & Baker, A. C. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31734 · Cited by 1
What Child Neurologists Need to Know About Pediatric Glioma
Younes, S. T., & Chintagumpala, M. (2025) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2025.05.029 · Cited by 1
Hurley, C., Nardo, M. D., Rees, M. G., Hijano, D. R., Said, A. S., Sharma, A., Elbahlawan, L. M., Hines, M., McArthur, J. A., Sandhu, H. S., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1588403 · Cited by 1
Advancements in CDK-based Dual-target Inhibitors for Cancer Therapy
Dou, B., Zhang, H., & Cui, Y. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673368870250602112835 · Cited by 1
Quinlan, L., Page, E. C., Rehn, J. A., McClure, B. J., Osborn, M. P., Moore, A. S., Kotecha, R. S., Henderson, M. J., Martin, M., Alvaro, F., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31983 · Cited by 1
Emerging interventional treatments in the management of pediatric brain tumors
Shatara, M., Ho, W. S., Roland, J. L., & Limbrick, D. D. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.09.004 · Cited by 1
Skok, K., Ochsenhofer, F., Gassner, R., Leithner, A., Szkandera, J., Viertler, C., Hasenschwandtner, S., Reichinger, A., & Liegl‐Atzwanger, B. (2025) · Communications Medicine · doi:10.1038/s43856-025-01184-z · Cited by 1
Zhu, F., Cheng, H., Han, Y., Shen, Y., Zhu, Z., Ren, Q., Su, Y., Wang, Z., Qin, H., Yang, W., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf401 · Cited by 1
Xie, C., Ke, J., & Liu, F. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.008 · Cited by 1
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
